Pharma stocks buck market weakness as Dr Reddy’s gains
Pharma stocks showed strength on Thursday, defying market weakness. Dr Reddy’s Laboratories saw significant gains, fueled by anticipation of approval for its Semaglutide diabetes drug in Canada. Other pharma companies also experienced upward movement. This defensive sector appeal is attracting investors amid uncertain market conditions and geopolitical concerns.
IT majors see strong deal pipeline but revenue momentum cools in Q4
Indian IT firms are seeing steady new deals and operating margins. However, revenue growth is slowing down quarter-on-quarter because projects are delayed. Artificial intelligence also poses a risk to future earnings. Companies like Infosys and HCLTech have given cautious growth forecasts for the upcoming financial year. IT stocks may face pressure in the short term.